Biotechnology
Remote Pre-Approval Inspection Completed by EMA on WuXi Biologics' MFG4 Facility
WUXI, China, March 3, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that the European Medicines Agency (EMA) has completed a remote Pre-Approval Inspection (PAI) on its drug substance facility ...
2021-03-03 18:23
451
Seegene's Latest COVID-19 Test Can Simultaneously Target 4 Genes of SARS-CoV-2 and Recognize Multiple Virus Variants
* Seegene's new product filters COVID-19 and variants during primary PCR testing in 1 hr 55 minutes * Seegene's proprietary high multiplex technology enables detection of 10 different targets * S. Korean firm to research additional versions of variant diagnostic tests SEOUL, South Korea,...
2021-03-03 09:20
738
AGC Biologics Announces the Expansion of Their Cell and Gene Therapy Facility in Milan, Italy
SEATTLE, March 3, 2021 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced plans for the expansion of their Cell and Gene Therapy Center of Excellence inMilan, to increase capacities and implement viral vector su...
2021-03-03 08:00
1054
Sunquest Lauded by Frost & Sullivan for Driving Efficiency and Compliance with Its Differentiated Molecular Laboratory Information Management System
Sunquest provides various interoperable products and services that work with each other to improve lab efficiency and results accuracy LONDON, March 2, 2021 /PRNewswire/ -- Based on its recent analysis of the North American laboratory information management systems (LIMS) market for molecular an...
2021-03-02 22:00
723
Global Cord Blood Corporation Announces Receipt of Unsolicited Non-Binding Acquisition Proposal
HONG KONG, March 2, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that its board of directors (the "...
2021-03-02 20:00
4672
Merck and GPHL Collaborate on Business Innovation and Development in the Greater Bay Area
GUANGZHOU, China, March 2, 2021 /PRNewswire/ -- Merck, a leading science and technology company, today signed a Memorandum of Understanding (MOU) to begin strategic collaboration with Guangzhou Pharmaceutical Holdings Limited (GPHL), China's leading pharmaceutical company. The collaboration aim...
2021-03-02 18:12
1933
Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX® (Sumatriptan Nasal Spray, 20 mg)
MUMBAI, India, March 2, 2021 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereinafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Food and Drug...
2021-03-02 16:01
1788
Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB
SYDNEY, March 2, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB (STO: OASM), an innovation-focuse...
2021-03-02 07:00
2739
INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18
Trial achieved primary and secondary efficacy endpoints among all evaluable subjects in the Phase 3 multi-center, randomized, double-blind, placebo-controlled trial VGX-3100 is the first DNA medicine to achieve efficacy endpoints in a Phase 3 clinical trial INOVIO also continues to partner with...
2021-03-02 05:05
2684
Merck Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
- Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care - A Phase II trial reported that xevinapant plus che...
2021-03-01 18:48
1816
Avalon SteriTech and SoftBank Robotics Group Launch New Joint Venture to Develop and Promote Innovative Public Healthcare and Hygiene Solutions
HONG KONG, March 1, 2021 /PRNewswire/ -- Avalon SteriTech Limited ("Avalon") and SoftBank Robotics Group ("SBRG") today announced a joint venture focusing on the development of innovative products and technologies that strive to empower and benefit public health and well-being. The joint venture ...
2021-03-01 13:00
901
Sciwind's Investigational New Drug Approved for NASH Trial
HANGZHOU, China, March 1, 2021 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd., (Sciwind), a clinical-stage, fast-growing biotech focusing on research and development of innovative biologics, today announced that XW003, a potential candidate for the treatment of non-alcoholic steatohepatit...
2021-03-01 09:00
801
Innovent Announces First Patient Outside China Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody
SAN FRANCISCO and SUZHOU, China, March 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2021-03-01 08:23
3462
Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index
SHANGHAI and HONG KONG, March 1, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...
2021-03-01 08:00
955
Debiopharm And Genome & Company Join Forces To Create New Highly Specific Therapies For Cancer Patients
Korean and Swiss based companies leverage their oncology expertise to initiate a research collaboration to formulate novel antibody-drug conjugate (ADC) candidates LAUSANNE, Switzerland and SEONGNAM-SI GYEONGGI-DO, South Korea, Feb. 26, 2021 /PRNewswire/ -- Genome & Company (CEO:Jisoo Pae, Hanso...
2021-02-26 19:14
1840
Global Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2021
HONG KONG, Feb. 25, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for...
2021-02-25 05:16
8484
Zymergen Appoints Global Finance Expert Enakshi Singh as Chief Financial Officer
EMERYVILLE, Calif., Feb. 24, 2021 /PRNewswire/ -- Biofacturing leader Zymergen today announced it has promotedEnakshi (Ena) Singh to Chief Financial Officer. Singh has helped Zymergen close more than$1B in equity financing and $100M in debt since joining Zymergen as vice president of finance in 2...
2021-02-24 22:30
2564
VLP BioTech, Inc. Announces an Immunotherapy Designed for the Treatment of Chronic HBV/HDV Infections
- VLP BioTech Has Developed a Vaccine-Based Viral-Entry-Inhibitor for the Treatment of Chronic HBV/HDV. - The Vaccine-Based Treatment Has Significant Advantages Compared to a Peptide-Based, Entry-Inhibitor (Hepcludex). SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- VLP BioTech, Inc., a private, pre...
2021-02-24 22:00
1622
INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia
- Liquid biopsy-based precision test guides patient selection and offers potential for cost-effective, non-invasive alternative to surgical removal of cervical lesions - QIAGEN's bioinformatic expertise raises predictive biomarker power in INOVIO's patient selection - First-in-class next genera...
2021-02-24 14:45
4270
Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPA
SHANGHAI and HONG KONG, Feb. 24, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and onco...
2021-02-24 08:00
1206
Week's Top Stories
Most Reposted
Marriott International Pilots AI Solutions to Streamline Hotel Design Process for Future Properties in Asia-Pacific
[Picked up by 107 media titles]
2021-03-02 14:00
X-Creator Challenge Opens for Global Submissions Centering on Intelligent Equipment Solutions for Emergency and Disaster Rescue
[Picked up by 102 media titles]
2021-02-26 20:41
Revolut Singapore drives everyday use of card with cashback of up to 20% for public transport spend this March and April
[Picked up by 100 media titles]
2021-03-02 11:10"Horizontally to the Side, Vertically to the End": Establishing a Large Pattern of Poverty Alleviation Through Science and Technology
[Picked up by 94 media titles]
2021-03-01 22:02
TikTok Partners with FIGHT Esports for the #TikTokGGPH Creator Cup Tournament
[Picked up by 93 media titles]
2021-02-26 14:44
Most Read
iClick Issues Clarification on Acquisition of Parllay
2021-02-26 11:00
9838
Puxin Announces US$69 Million Private Placement of Convertible Notes
2021-02-26 20:00
9549
KBSF signed MOU of $1,500,000 to be used by Luxventure, its Social Media Platform
2021-02-27 04:00
9162
HUYA Inc. Announces Changes to Board Composition
2021-02-26 19:00
8281